Division of Gynecological Tumor
Division of Gynecological Tumor

SYSMH was one of the earliest institutions in China to perform gynecologic oncology surgeries. Currently, the Division of Gynecological Tumor has developed into a nationally influential department. It boasts a strong medical and nursing team, with nearly one hundred beds, admitting patients from across the country. It serves as a research station for Sun Yat-sen University's undergraduate, master's, doctoral, and postdoctoral programs, a training base for visiting scholars and standardized resident physician training, the nation's only standardized training base for hyperthermic intraperitoneal chemotherapy (HIPEC) in gynecologic oncology, and a dual demonstration unit for both "Multidisciplinary Team (MDT) for Gynecologic Malignancies" and "Gynecologic Oncology Clinical Research" under the Gynecologic Oncology Committee of the Chinese Anti-Cancer Association.
The Division of Gynecological Tumor is dedicated to improving the curative surgical and comprehensive treatment outcomes for gynecologic malignancies such as cervical, endometrial, ovarian, vulvar, and vaginal cancers. It holds a leading domestic position in radical hysterectomy with pelvic lymphadenectomy, fertility-sparing and ovary/sexual function-preserving radical surgeries for cervical cancer, radical vulvectomy with reconstruction, among others. The specialty has pioneered numerous "Yixian Surgical Techniques," including extensive cervical resection with functional reconstruction. By refining traditional procedures, it has simplified, standardized, and made complex and challenging surgeries like radical hysterectomy and pelvic lymphadenectomy more accessible for learning, promoting their adoption nationwide and contributing to the advancement of gynecologic surgical standards in China. Furthermore, it applies open surgical principles to laparoscopy, achieving a laparoscopy level that is also domestically leading.
The hospital was among the earliest in China to perform hysteroscopic procedures. It is currently a National Level IV Gynecological Endoscopy Training Base. Its expertise in diagnosing and treating conditions such as intrauterine adhesions, intrauterine foreign bodies, uterine malformations, intrauterine tumors and lesions, and vaginal tumors in infants and young children is at the forefront in China.
The Division of Gynecological Tumor is committed to promoting the world's most authoritative standardized diagnosis and treatment guidelines for gynecologic cancers. Whenever FIGO (International Federation of Gynecology and Obstetrics) and NCCN (National Comprehensive Cancer Network) guidelines for various gynecologic malignancies are updated, the specialty authors and publishes guideline interpretations in journals to disseminate them. Since establishing the "Yixian Gynecologic Oncology" public platform in 2016, it has used this channel to promote the latest authoritative guidelines, standardized diagnosis, treatment, and surgical practices for gynecologic tumors, and to provide consultation for complex cases nationwide, earning widespread recognition and praise from peers.

More

Featured Medical Technology

The Division of Gynecological Tumor of SYSMH, widely recognized in the field as "Yixian Gynecologic Oncology," is followed by nearly all gynecologic oncologists in China. The department is a National Clinical Key Specialty, a Guangdong Provincial Key Discipline, a Guangdong Provincial Clinical Key Specialty, and a Guangdong Provincial Clinical Distinctive Specialty, as well as a National Endoscopy Training Base. We organize national and provincial continuing medical education courses annually, supporting hospitals at various levels both nationally and within the province to help peers learn and advance.
Clinically, the most advanced minimally invasive technologies in the field are comprehensively applied to gynecologic oncology, including robotic surgery, laparoscopy, single-port laparoscopy, hyperthermic intraperitoneal chemotherapy (HIPEC), and CUSA (Cavitron Ultrasonic Surgical Aspirator). Concurrently, our traditional open surgery and transvaginal surgical techniques have become benchmarks for domestic peers, attracting numerous specialists for advanced training each year. As a national promotion center for world-authoritative gynecologic cancer diagnosis and treatment guidelines, our department holds a leading national position in open gynecologic oncology surgery and complex gynecologic procedures, with hysteroscopic diagnosis and treatment capabilities leading in South China. For many years, we have performed hundreds of surgeries annually for cervical, ovarian, and endometrial cancers. We also treat various complex conditions such as refractory gestational trophoblastic neoplasia, uterine prolapse, rectovaginal fistula, reproductive tract malformations, intrauterine diseases, infertility, and refractory gynecologic tumors.
We employ the most advanced anti-tumor treatment modalities, including targeted therapy, immunotherapy, and physical therapy, providing precise treatment at the genetic level. The department conducts both registered and non-registered clinical trials for new anti-tumor drugs and technologies, offering assistance to patients with gynecologic malignancies at all stages.

More

Scientific Research Results

Over the past five years, we have secured more than 30 research projects, including the National Natural Science Foundation General Program and Young Scientists Program, the Ministry of Education Ph.D. Programs Foundation, the Ministry of Health Clinical Key Specialty Project, provincial key science and technology programs, and major municipal industry-university-research projects. We have compiled a series of publications on gynecologic oncology, including Chemotherapy Manual for Gynecologic Malignancies, Diagnosis and Treatment Pathways for Gynecologic Tumors, and Case Studies in Yixian Gynecologic Oncology, as well as the "12th Five-Year Plan" textbook of the Ministry of Health: Obstetrics and Gynecology. We have published multiple interpretations of authoritative industry guidelines, covering cervical cancer, uterine cancer, ovarian cancer, gestational trophoblastic neoplasia, and targeted therapy for ovarian cancer. More than 300 SCI-indexed research articles have been published, and we have served as chief editors or contributors to over 30 monographs. Our professional papers have been included in conferences such as ESMO and ESGE.
The department hosts numerous postgraduate students and visiting physicians. We have achieved significant results in undergraduate teaching, postgraduate education, and continuing medical education, receiving several teaching grants and awards at the provincial, university, and hospital levels.

More